Evidence map›Paper›PMID 32197348›Full record

ArticleVaccines2020

Comparisons of Antibody Populations in Different Pre-Fusion F VLP-Immunized Cotton Rat Dams and Their Offspring.

Lori M Cullen, Marina S Boukhvalova, Jorge C G Blanco, Trudy G Morrison

Open access · goldAbstract read
In one paragraph

Article in Vaccines, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Lori M CullenDepartment of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, MA 01655, USA.
Marina S BoukhvalovaSigmovir Biosystems Inc., Rockville, MD 20850, USA.
Jorge C G BlancoSigmovir Biosystems Inc., Rockville, MD 20850, USA.ORCID 0000-0002-6173-0213
Trudy G MorrisonDepartment of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, MA 01655, USA.
Sigmovir Biosystems (United States) · USUniversity of Massachusetts Chan Medical School · US

Funding

Development of VLP vaccine for RSVR44AI109926 · NIAID · SIGMOVIR BIOSYSTEMS, INC. · PI BLANCO, JORGE C · 2019 to 2021
$3.5M
Development of VLP vaccine for RSVR42AI109926 · NIAID · SIGMOVIR BIOSYSTEMS, INC. · PI BLANCO, JORGE C · 2016 to 2017
$1.9M
Development of VPL Vaccine for RSVR41AI109926 · NIAID · SIGMOVIR BIOSYSTEMS, INC. · PI BLANCO, JORGE C · 2014 to 2014
$225k
National Institute of Allergy and Infectious Diseases AI109926, AI114809NIAID NIH HHS R41 AI109926NIAID NIH HHS R42 AI109926NIAID NIH HHS R44 AI109926
6 · The paper itself

Abstract

Respiratory syncytial virus (RSV) infection poses a significant risk for infants. Since the direct vaccination of infants is problematic, maternal vaccination may provide a safer, more effective approach to their protection. In the cotton rat (CR) model, we have compared the immunization of pregnant CR dams with virus-like particles assembled with the prototype mutation stabilized pre-fusion F protein, DS-Cav1, as well two alternative mutation stabilized pre-fusion proteins (UC-2 F, UC-3 F) and showed that the alternative pre-fusion F VLPs protected the offspring of immunized dams significantly better than DS-Cav1 F VLPs (Blanco, et al. J. Virol. 93: e00914). Here, we have addressed the reasons for this increased protection by characterizing the specificities of antibodies in the sera of both immunized dams and their offspring. The approach was to measure the levels of total anti-pre-F IgG serum antibodies that would block the binding of representative pre-fusion specific monoclonal antibodies to soluble pre-fusion F protein targets. Strikingly, we found that the sera in most offspring of DS-Cav1 F VLP-immunized dams had no mAb D25-blocking antibodies, although their dams had robust levels. In contrast, all offspring of UC-3 F VLP-immunized dams had robust levels of these D25-blocking antibodies. Both sets of pup sera had significant levels of mAb AM14-blocking antibodies, indicating that all pups received maternal antibodies. A lack of mAb D25-blocking antibodies in the offspring of DS-Cav1 F VLP-immunized dams may account for the lower protection of their pups from challenge compared to the offspring of UC-3 F VLP-immunized dams.

Indexed as

antibodiesmaternal antibodiespre-fusion F proteinsvaccinesvirus-like particles

Identifiers

PMID32197348
PMCPMC7157610
OpenAlexW3011046432

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.